Amylyx Pharmaceuticals (AMLX) Current Leases (2022 - 2026)

Amylyx Pharmaceuticals' Current Leases history runs 5 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• In Q1 2026, Current Leases rose 9.48% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (up 9.48% YoY), while the FY2025 annual figure was $1.3 million, down 17.06% from the prior year.
• Current Leases was $1.2 million for Q1 2026 at Amylyx Pharmaceuticals, down from $1.3 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $2.4 million in Q2 2024 to a low of $665000.0 in Q2 2025.
• Historically, Current Leases has averaged $1.7 million across 5 years, with a median of $2.0 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Current Leases soared 48.97% in 2023, then slumped 71.93% in 2025.
• A 5-year view of Current Leases shows it stood at $2.0 million in 2022, then rose by 10.64% to $2.3 million in 2023, then sank by 32.74% to $1.5 million in 2024, then dropped by 17.06% to $1.3 million in 2025, then decreased by 8.26% to $1.2 million in 2026.
• The last three Current Leases figures came in at $1.2 million (Q1 2026), $1.3 million (Q4 2025), and $981000.0 (Q3 2025), per Business Quant data.